BACKGROUND: Gemcitabine is an efficacious cytotoxic agent used in the treatment of unresectable pancreatic carcinoma (PC). Recently, gemcitabine resistance has been associated with the ribonucleotide reductase subunit M2 (RRM2). In this prospective study, we hypothesized that RRM2 expression in PC biopsy specimens would be a significant predictor of outcome. METHODS: RRM2 mRNA expression in 35 endoscopic ultrasonography-guided fine needle aspiration biopsy (EUS-FNAB) samples was quantified using real-time quantitative reverse transcription-polymerase chain reaction. RESULTS: Thirty-one of 35 biopsy specimens could be assessed for RRM2 expression levels. The mean RRM2 expression relative to glyceraldehyde-3-phosphate dehydrogenase was 0.248 (range, 0.00739 to 0.858). Eighteen patients (64.5%) had low RRM2 levels, and 13 patients (35.5%) had high RRM2 levels with a cutoff of 0.1. The median survival was 8.8 months for patients with low RRM2 levels and 5.0 months for patients with high levels (P < 0.05). In the low RRM2 expression group, a complete response (CR) was observed in one patient, and a partial response (PR) was observed in eight patients. In contrast, in the high RRM2 expression group, PR was observed in one patient, and CR was not observed. The overall response rate between the high and low expression groups was significantly different (50.0% vs. 7.7%, P < 0.05). CONCLUSIONS: RRM2 mRNA expression of EUS-FNAB specimens is a key predictive marker of survival in gemcitabine-treated patients with PC.
BACKGROUND:Gemcitabine is an efficacious cytotoxic agent used in the treatment of unresectable pancreatic carcinoma (PC). Recently, gemcitabine resistance has been associated with the ribonucleotide reductase subunit M2 (RRM2). In this prospective study, we hypothesized that RRM2 expression in PC biopsy specimens would be a significant predictor of outcome. METHODS:RRM2 mRNA expression in 35 endoscopic ultrasonography-guided fine needle aspiration biopsy (EUS-FNAB) samples was quantified using real-time quantitative reverse transcription-polymerase chain reaction. RESULTS: Thirty-one of 35 biopsy specimens could be assessed for RRM2 expression levels. The mean RRM2 expression relative to glyceraldehyde-3-phosphate dehydrogenase was 0.248 (range, 0.00739 to 0.858). Eighteen patients (64.5%) had low RRM2 levels, and 13 patients (35.5%) had high RRM2 levels with a cutoff of 0.1. The median survival was 8.8 months for patients with low RRM2 levels and 5.0 months for patients with high levels (P < 0.05). In the low RRM2 expression group, a complete response (CR) was observed in one patient, and a partial response (PR) was observed in eight patients. In contrast, in the high RRM2 expression group, PR was observed in one patient, and CR was not observed. The overall response rate between the high and low expression groups was significantly different (50.0% vs. 7.7%, P < 0.05). CONCLUSIONS:RRM2 mRNA expression of EUS-FNAB specimens is a key predictive marker of survival in gemcitabine-treated patients with PC.
Authors: R A Finch; M Liu; S P Grill; W C Rose; R Loomis; K M Vasquez; Y Cheng; A C Sartorelli Journal: Biochem Pharmacol Date: 2000-04-15 Impact factor: 5.858
Authors: E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: Rafael Rosell; Kathleen D Danenberg; Vincente Alberola; Gerold Bepler; Jose Javier Sanchez; Carlos Camps; Mariano Provencio; Dolores Isla; Miquel Taron; Pilar Diz; Angel Artal Journal: Clin Cancer Res Date: 2004-02-15 Impact factor: 12.531
Authors: Rafael Rosell; Giorgio Scagliotti; Kathleen D Danenberg; Reginald V N Lord; Gerold Bepler; Silvia Novello; Janine Cooc; Lucio Crinò; José Javier Sánchez; Miquel Taron; Corrado Boni; Filippo De Marinis; Maurizio Tonato; Maurizio Marangolo; Felice Gozzelino; Franceso Di Costanzo; Massimo Rinaldi; Dennis Salonga; Craig Stephens Journal: Oncogene Date: 2003-06-05 Impact factor: 9.867
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: W Scheithauer; G V Kornek; M Raderer; M Hejna; J Valencak; J Miholic; E Kovats; F Lang; J Funovics; E Bareck; D Depisch Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: Barbara Bournet; Marion Gayral; Jérôme Torrisani; Janick Selves; Pierre Cordelier; Louis Buscail Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: James J Farrell; Jennifer Moughan; Jonathan L Wong; William F Regine; Paul Schaefer; Al B Benson; John S Macdonald; Xiyong Liu; Yun Yen; Raymond Lai; Zhong Zheng; Gerold Bepler; Chandan Guha; Hany Elsaleh Journal: Pancreas Date: 2016-11 Impact factor: 3.327
Authors: Christina H Wei; Tristan R Gorgan; David A Elashoff; O Joe Hines; James J Farrell; Timothy R Donahue Journal: Pancreas Date: 2013-11 Impact factor: 3.327